PASENIN – HYPOLIPIDEMIC DRUG OF TRIGONELLA FOENUM-GRAECUM L

DOI: https://doi.org/10.29296/25877313-2018-10-13
Issue: 
10
Year: 
2018

V.V. Karabaeva Senior Research Scientist, Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E-mail: vera-karabaeva@rambler.ru G.F. Sidelnikovа Research Scientist, Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) L.V. Krepkova Ph.D. (Biol.), Head of Toxicology Department, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E-mail: krepkowa2011@yandex.ru V.V. Bortnikova Ph.D. (Biol.), Leading Research Scientist, Department of Toxicology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E.V. Ferubko Ph.D. (Med.), Head of Experimental and Clinical Pharmacology Department, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow)

Рurpose: summary of results of experimental and clinical studies Pasеnin – hypolipidemic agents of plant origin. Methods: Pasеnin obtained from the seeds of fenugreek (Trigonella foenum-graecum L.), leguminous (Fabáceae). Active ingredients Pasеnin is the sum of furostanol glycosides (minimum 80 %), the main of which is protoyamoscin (about 50 % of the total content). Pasеnin dosage form – tablets of 0.03 g for oral administration. Results: experimental study Pasеnin on the model of hyperlipidemia in rats and rabbits have established a clear dose-dependent hypolipidemic (hypotriglyceridemic and cholesterol-lowering) effect. Introduction Pasеnin reduced fatty degeneration of internal organs and the development of compli-cations associated with atherosclerosis of main coronary arteries of rats, which indicated not only hypolipidemic, but also angio - and cardioprotective ac-tion. Pasеnin somewhat reduced the glucose content in the blood of experimental animals and decreased blood clotting. Clinical studies of the efficacy and safety of Pasenin were conducted in 4 hospitals with 212 patients aged 20-70 years of male and female with various types of dyslipidemia (IIa, IIb, IV). The appointment of Pasenin led to a decrease in the level of total cholesterol, triglycerides, LDL, apolipoprotein B, an increase in the concentration of apolipoprotein a-1, normalization of HDL and reduce the atherogenic index. Pasenin reduced level of glucose in blood and improve microvascular blood flow. Good tolerability of the drug was established in all patients. Conclusions: Experimental and clinical studies have shown that Pasenin has a hypolipidemic (cholesterol-lowering and hypotriglyceridemic) prop-erties and can be used in the treatment of dyslipidemias, accompanying cardiovascular pathology and diabetes

Keywords: 
pasenin
Trigonella foenum-graecum
dyslipidemia
hypolipidemic
hypocholesterinemic
hypotriglyceridemic properties

References: 
  1. Sergienko I.V., Ansheles A.A., Kuharchuk V.V. Ateroskleroz i dislipidemii: sovremennye aspekty patogeneza, diagnostiki i lechenija. M.: PatiSS. 2017. 140 s.
  2. Aronov D.M., Lupanov V.P. Nekotorye aspekty patogeneza ateroskleroza // Ateroskleroz i dislipidemii. 2011. № 1. S. 48-56.
  3. Rekomendatsii Evropejskogo obschestva kardiologov i Evropejskogo obschestva ateroskleroza po lecheniju dis-lipidemij // Ratsional'naja Farmakoterapija v Kardiologii. 2012. Prilozhenie № 1. 60 s.
  4. Diagnostika i korrektsija narushenij lipidnogo obmena s tsel'ju profilaktiki i lechenija ateroskleroza. Rossijskie rekomendatsii. VI peresmotr. M., 2017. S. 44.
  5. Rekomendatsii EOK/EOA po diagnostike i lecheniju dislipidemij 2016 // Rossijskij kardiologicheskij zhurnal. 2017. T. 5. № 145. S. 7–77 [Elektronnyj resurs]. http://dx.doi.org/10.15829/1560-4071-2017-5-7-77.
  6. Klinicheskaja farmakologija i farmakoterapija: Uchebnik. Izd. 3-e, pererab. i dop. / Pod red. V.G. Kukesa, A.K. Starodubtseva. 2012. 840 s.
  7. Krepkova L.V., Bortnikova V.V., Arzamastsev E.V., Kuznetsov Ju.B. Toksikologicheskaja harakteristika fitopreparatov gipolipidemicheskogo dejstvija na modeli ateroskleroza u krys // Trudy Vserossijskogo nauchno-is-sledovatel'skogo instituta lekarstvennyh i aromaticheskih rastenij. Ser. Himija, tehnologija, meditsina. 2004. S. 220-226.
  8. Ryff I.M., Krepkova L.V., Arzamastsev E.V. i dr. Patomorfologicheskie kriterii antiateroskleroticheskogo dejstvija nekotoryh saponinov rastitel'nogo proishozhdenija v eksperimente // Bjulleten' eksperimental'noj biologii i meditsiny. 1988. № 9. S. 365-368.
  9. Krepkova L.V. Ispol'zovanie modeli giperlipidemii i ateroskleroza u krys v toksikologicheskom eksperimente // Biomeditsina. 2011. № 3. S. 103-106.